Quality by design approach for formulation development: A case study of dispersible tablets

International Journal of Pharmaceutics

Volumn 423, Issue 2, 2012, Pages 167-178

  Charoo, Naseem A ^a   Shamsher, Areeg A A ^b   Zidan, Ahmed S ^c,d   Rahman, Ziyaur ^d  

^a Blue Nile Pharmaceutical Company   (Sudan)

^b RAK MEDICAL AND HEALTH SCIENCES UNIVERSITY   (United Arab Emirates)

^c Zagazig University   (Egypt)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Control strategy; Critical quality attributes; Design space; Dispersible tablets; Quality by design; Risk assessment

Indexed keywords

CROSCARMELLOSE SODIUM; DICLOFENAC; MAGNESIUM STEARATE; MICROCRYSTALLINE CELLULOSE; STARCH GLYCOLATE SODIUM;

ARTICLE; DISPERSIBLE TABLET; DRUG DEGRADATION; DRUG DESIGN; DRUG IMPURITY; DRUG PACKAGING; DRUG SOLUBILITY; EXCIPIENT COMPATIBILITY; PACKAGING MATERIAL; PARTICLE SIZE; PATIENT COMPLIANCE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; QUALITY CONTROL; RISK MANAGEMENT; RISK REDUCTION; SHELF LIFE; TABLET COMPRESSION; TABLET DISINTEGRATION TIME; TABLET FORMULATION; TABLET HARDNESS; TABLET PROPERTY; TOTAL QUALITY MANAGEMENT;

CHEMISTRY, PHARMACEUTICAL; CONSUMER PRODUCT SAFETY; DICLOFENAC; DRUG COMPOUNDING; DRUG PACKAGING; DRUG STABILITY; EXCIPIENTS; HARDNESS; HARDNESS TESTS; KINETICS; LUBRICANTS; PARTICLE SIZE; QUALITY CONTROL; RISK MANAGEMENT; SOLUBILITY; TABLETS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84856524155     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.12.024     Document Type: Article

References (44)

1. N.A. Armstrong Pharmaceutical Experimental Design and Interpretation 2nd ed. 1998 CRC Press Taylor and Francis Group Boca Raton, FL
2. Application of hazard analysis and critical control point (HACCP) methodology to pharmaceuticals. WHO Technical Report Series No 908, 2003 Annex 7. http://apps.who.int/medicinedocs/en/d/Js5517e/23.html (accessed on July 28, 2011).
3. G.S. Banker, A.Y. Gore, and J. Swarbrick Water vapour transmission properties of applied polymer films J. Pharm. Pharmacol. 18 1966 205S 211S
4. F. Boukouvala, F.J. Muzzio, and M.G. Ierapetritou Design space of pharmaceutical processes using data-driven-based methods J. Pharm. Innov. 5 2010 119 137
5. British Pharmacopeia Convention, Market Towers, 1 Nine Elms Lane, London SW8 5NQ, BP 2009.
6. British standard BS: IEC61882:2002 Hazard and operability studies (HAZOP studies) - application guide British standards institution. This British standard reproduces verbatim IEC 61882:2001 and implements it as the UK national standard.
7. http://www.ingenieroambiental.com/4002/ BS%20IEC%2061882%202001%20HAZOP%20guide.pdf (accessed on July 28, 2011).
8. R.L. Carr Jr. Evaluating flow properties of solids Chem. Eng. 18 1965 163 166
9. B. Chuasuwan, V. Binjesoh, J.E. Polli, H. Zhang, G.L. Amidon, H.E. Junginger, K.K. Midha, V.P. Shah, S. Stavchansky, J.B. Dressman, and D.M. Barends Biowaiver monographs for immediate release solid oral dosage forms: diclofenac sodium and diclofenac potassium J. Pharm. Sci. 98 2009 1206 1219
10. D.W. David, W.B. Steven, A.J. Ross, R.M. Steven, S.M. Marybeth, K.H. Diana, and M.G. Stephen Maillard reaction of lactose and fluoxetine hydrochloride, a secondary amine J. Pharm. Sci. 87 1998 31 39
11. J.M. Delasko, D.M. Cocchetto, and L.B. Burke Target product profile: beginning drug development with the end in mind Update 1 2005 36 39
12. EMEA Guideline on real time release testing. EMEA/CHMP/QWP/811210/2009 Rev 1, 25 February 2010. http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2010/03/WC500075028.pdf (accessed on July 28, 2011).
13. C.E. Ericson Hazard analysis techniques for system safety 2005 Wiley-Interscience p. 528
14. Federal Food, Drug and Cosmetic Act (FDCA), 1962. sec. 201(p)(1), sec. 201(p)(2), 21 U.S.C. 321(p)(1), (p)(2); Pub. L., pp. 87-781.
15. R.A. Fisher The Design of Experiments 1926 Oliver and Boyd London
16. Food and Drugs Act of 1906. Public Law 59-384. 34 U.S. Stat. 30 June 1906, 768.
17. Janssen, W.F., 1981. The Story of the Laws Behind the Labels, Part I, 1906 Food and Drugs Act, Part II, 1938 The Federal Food, Drug, and Cosmetic Act., Part III, 1962 Drug Amendments, FDA Consumer, June (available on FDA website; Part 3 history1b).
18. Food and Drug Administration, 2003. Final report on pharmaceutical cGMPs for the 21st century-A risk-based approach.
19. Food and Drug Administration, 2004. Guidance for industry. PAT - a framework for innovative pharmaceutical development, manufacturing, and quality assurance. September.
20. Food and Drug Administration, May 2006. Guidance for industry. Q8 pharmaceutical development.
21. Food and Drug Administration CDER, March 2007. Draft guidance for industry and review staff: Target product profile-strategic development tool.
22. http://www.fda.gov/cder/gmp/gmp2004/GMP-finalreport2004.htm (accessed on July 29).
23. Food and Drug Administration CDER, November 2009. Guidance for industry Q8 (R2) pharmaceutical development.
24. M. Glodek, S. Liebowitz, R. McCarthy, G. Mcnally, C. Oksanen, and T. Schultz Process robustness - a PQRI white paper Pharm. Eng. 2006 1 11
25. Y.Y. Haimes, S. Kaplan, and J.H. Lambert Risk filtering, ranking, and management framework using hierarchical holographic modelling Risk Anal. 22 2002 383 397 (Pubitemid 34533265)
26. Hiyama, Y., 2011. Quality overall summary mock P2 (description examples) March 2009. http://www.nihs.go.jp/drug/section3/English%20Mock%20QOS%20P2%20R. pdf (accessed on July 28, 2011).
27. J. Huang, G. Kaul, C. Cai, R. Chatlapalli, P.H. Abad, K. Ghosh, and A. Nagi Quality by design case study: an integrated multivariate approach to drug product and process development Int. J. Pharm. 382 2009 23 32
28. M.S.H. Hussain, P. York, P. Timmins, and P. Humphrey Secondary ion mass spectrometry (SIMS) evaluation of magnesium stearate distribution and its effects on the physico-technical properties of sodium chloride tablets Powder Technol. 60 1990 39 45 (Pubitemid 20645395)
29. ICH harmonised tripartite guideline, November 2005. Quality risk management Q9.
30. ICH harmonised tripartite guideline, November 2000. Guideline Q7A: good manufacturing practices for active pharmaceutical ingredients.
31. ICH harmonised tripartite guideline, June 2008. Pharmaceutical quality systems Q10.
32. International Society for Pharmaceutical Engineering, 2010. Baseline pharmaceutical engineering guide volume 7: Risk-based manufacture of pharmaceutical products: a guide to managing risks associated with cross-contamination. First Edition, September 2010.
33. J. Lepore, and J. Spavins PQLI design space J. Pharm. Innov. 3 2008 79 87
34. R.A. Lionberger, S.L. Lee, L. Lee, A. Raw, and L.X. Yu Quality by design: concepts for ANDAs AAPS J. 10 2008 268 276
35. T. Lipsanen, O. Antikainen, H. Räikkönen, S. Airaksinen, and J. Yliruusi Novel description of a design pace for fluidised bed granulation Int. J. Pharm. 345 2007 101 107 (Pubitemid 350087547)
36. B. Davis, L. Lundsberg, and G. Cook PQLI control strategy model and concepts J. Pharm. Innov. 3 2008 95 104
37. R.L. Plackett, and J.P. Burman The design of optimum multifactorial experiments Biometrika 33 1946 305
38. F.A. Menard Quality by design in generic drug development Presentation to FDA Office of Generic Drugs September 2006
39. A.S. Rathore, R. Branning, and D. Cecchini Design space for biotech products Biopharm. Int. 20 2007 36 40 (Pubitemid 46658621)
40. D.L. Rosen Generic drug approval process: pre-1984 history concerning generic drugs I.R. Berry, The Pharmaceutical Regulatory Process 2005 Marcel Dekker New York 99 106
41. R.F. Shangraw, and D.A. Demarest A survey of current industrial practices in the formulation and manufacture of tablets and capsules Pharm. Technol. 17 1993 32 44
42. US Food and Drug Administration/US Department of agriculture. Hazard analysis and critical control point principles and application guidelines. Adopted August 14, 1997. http://www.fda.gov/Food/FoodSafety/ HazardAnalysisCriticalControlPointsHACCP/HACCPPrinciplesApplicationGuidelines/ default.htm#guide (accessed on July 28, 2011).
43. U.S. Pharmacopeial Convention, Inc., 2007. 12601 Twinbrook Parkway, Rockville, MD 20852, p. 25.
44. "Voltarol", Summary of product characteristics, 2011. http://www.medicines.org.uk/EMC/medicine/1340/SPC/ Voltarol+Dispersible+Tablets+50mg/ (accessed on December 6, 2011).